癌症生物研究組

組長   張志隆 醫師

進駐研究醫師：翁嘉穗、林鈴、黃琬珺、陳思嘉、林玟瑄

研究人員

吳昭志 博士
許芸婷、邱柏瑄、蕭又嘉、林子淯、黃胤榮

本研究室的設置以探討癌症的分子生物特性並進以開發新治療策略為主要研究方向。目前的研究主題有：(1) 探索癌症化學治療之免疫調節，以提供臨床上優化癌症治療法之參考； (2) 奈米粒子對非侵入式癌症熱治療及藥物傳輸的應用； (3) 癌症幹細胞分離及其療法上之應用； (4) 婦科癌症診斷生物標誌之篩選； (5) 免疫細胞療法在婦科腫瘤應用之開發。實驗室的長期目標為發展及測試新式癌症治療策略，以成為臨床應用及改進的依據，並積極透過跨院際及跨領域合作，以擴展研究內容及增進實際臨床運用之可行性。

動物及人類抗腫瘤免疫分析
攜帶基因病毒載體備製
單株抗體發展與備製
免疫細胞培養
癌症幹細胞分離及應用
組織陣列樣品及切片之製備

實驗室主要核心技術有：(1)癌症免疫學分析，包含抗原專一性CD8+、CD4+及癌組織浸潤 T細胞的偵測，自然殺手細胞 (Nature killer cells, NK)及自然殺手T細胞 (Nature killer T cells, NKT) 之細胞毒殺能力分析，巨噬細胞吞噬能力分析，棘狀細胞抗原呈現能力測試以及B細胞增生分析；(2)單株抗體製備及人源化；(3)嵌合抗原受體及免疫細胞療法之備製；(4)組織陣列樣品及切片之製備；(5)奈米粒子之開發及製備；(6)腫瘤動物模式之建立等。過去五年共發表9篇國內外SCIE論文，並執行多個專題國科會計畫、一個國科會國家型科技計畫及兩個重點型計畫。

Chang CL, Wu CC, Hsu YT, Hsu YC. Immune vulnerability of ovarian cancer stem-like cells due to low CD47 expression is protected by surrounding bulk tumor cells. OncoImmunology 2020; 9(1):1803530. (SCIE, ONCOLOGY) (IF: 7.723, Ranking: 48/245 =19.59%)

Wu CC, Hsu YT, Chang CL. Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting. International Journal of Hyperthermia 2021; 38(1):1013-1022. (SCIE, RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING) (IF: 3.753, Ranking: 55/136 =40.44%)

Chang CL, Ho SC, Su YF, Juan YC, Huang CY, Chao AS, Hsu ZS, Chang CF, Fwu CW, Chang TC. DNA methylation marker for the triage of hrHPV positive women in cervical cancer screening: Real-world evidence in Taiwan. Gynecol Oncol 2021; 161(2):429-435. (SCIE, OBSTETRICS & GYNECOLOGY) (IF: 5.304, Ranking: 10/85=11.76%)

Lim L, Wang TY, Lam HB, Chang CL. Massive metastasis of breast cancer to female genital organs. Taiwanese Journal of Obstetrics and Gynecology 2021; 60(3):563-566. (SCIE, OBSTETRICS & GYNECOLOGY) (IF: 1.944, Ranking: 72/85 =84.71%)

Lim L, Wu CC, Hsu YT, Sun FJ, Chang CL. Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology 2019; 58(1):105-110. (SCIE, OBSTETRICS & GYNECOLOGY) (IF: 1.944, Ranking: 72/85 =84.71%)

Huang WC, Hsiao YC, Wu CC, Hsu YT, Chang CL. Less circulating mucosal-associated invariant T cells in patients with cervical cancer. Taiwanese Journal of Obstetrics and Gynecology 2019; 58(1):117-121. (SCIE, OBSTETRICS & GYNECOLOGY) (IF: 1.944, Ranking: 72/85 =84.71%)

Wu CC, Weng CS, Hsu YT, Chang CL. Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET. Taiwanese Journal of Obstetrics and Gynecology 2019; 58(1):145-152. (SCIE, OBSTETRICS & GYNECOLOGY) (IF. 1.944 , Ranking:72/85 =84.71%) 

Lee J, Chang CL, Lin JB, Wu MH, Sun FJ, Jan YT, Hsu SM, Chen YJ. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradiotherapy for locally advanced cervical cancer. Clinical Cancer Research 2018; 24(20):5028-5036. (SCIE, ONCOLOGY) (IF: 13.801, Ranking: 17/245 =6.94%)

Lee J, Chang CL, Lin JB, Wu MH, Sun FJ, Wu CJ, Tai HC, Hsu SM, Chen YJ. The effect of body mass index and weight change on late gastrointestinal toxicity in locally advanced cervical cancer treated with intensity-modulated radiotherapy. International Journal of Gynecological Cancer 2018; 28(7):1377-1386. (SCIE, OBSTETRICS & GYNECOLOGY) (IF: 4.661, Ranking: 13/85 =15.29%)